ArticleTranslational cancer research2025
Primary signet-ring cell carcinoma of the bile duct: clinical characteristics, survival comparison with cholangiocarcinoma, and SEER-based prognostic nomograms.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Signet-ring cell carcinoma (SRCC) of the bile duct is a rare malignancy with poorly characterized clinical features and prognosis. Given its rarity and the critical need to differentiate its behavior from common cholangiocarcinoma (CCA), this population-based study aimed to characterize SRCC and compare survival outcomes with CCA, while developing prognostic nomograms for individualized prediction. Methods: We analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database [2000-2021], identifying 98 SRCC and 18,979 CCA cases. Propensity score matching (PSM) analysis (1:5 ratio) was conducted to balance baseline characteristics between groups (98 SRCC Results: SRCC predominantly involved the extrahepatic bile duct (86.7%) and exhibited poor survival [median OS (mOS) 7.0 months, 95% confidence interval (CI): 4.0-10.0; median CSS (mCSS) 8.0 months, 95% CI: 5.0-12.0]. After PSM, no significant survival difference was observed between SRCC and CCA (P>0.05). Older age and distant metastasis were independent factors associated with poor survival, whereas surgery and chemotherapy were independently associated with better survival. The nomograms demonstrated moderate predictive accuracy (C-index: OS 0.78, 95% CI: 0.71-0.84; CSS 0.78, 95% CI: 0.70-0.85). Calibration curves showed excellent agreement between predicted and observed survival, ROC analysis confirmed discriminative ability, and DCA indicated strong clinical utility. Conclusions: SRCC of the bile duct is a rare, aggressive malignancy with a prognosis similar to CCA. The developed nomograms, integrating readily available clinical factors, provide clinically applicable tools for individualized prognosis prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.